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Abstract: The aim of this study was to determine the antibiotic susceptibility patterns of 57
Aggregatibacter actinomycetemcomitans and 56 Porphyromonas gingivalis strains isolated from subgingival
biofilm samples of periodontitis patients in Switzerland from 1980 to 2017. The minimal inhibitory
concentrations (MIC) of the most commonly used antibiotics in periodontal therapy (amoxicillin,
metronidazole, azithromycin, and doxycycline) or in severe body infections (amoxicillin/clavulanic
acid, clindamycin, ertapenem, and moxifloxacin) were determined. Furthermore, all the strains were
screened for beta-lactamase activity and the presence of selected resistance genes (cfxA, ermF, and
tetQ). Overall, there was no significant increase in MIC values over the 37-year period. Two of the most
recent P. gingivalis isolates yielded the highest MIC values. The first isolate was ermF-positive with
MIC values >8 µg/mL, 2 µg/mL, and 0.25 µg/mL for clindamycin, azithromycin, and moxifloxacin,
respectively. The second isolate showed a high MIC value of 4 µg/mL for moxifloxacin, which was
associated with a confirmed single-point mutation in the quinolone resistance-determining region
(QRDR) of the gyrA gene. Although there was no significant increase in the antibiotic resistance
among the oral bacterial isolates tested, the detection of resistant P. gingivalis isolates underlines the
need to optimize the antibiotic therapeutic protocols in dentistry.
Keywords: minimal inhibitory concentrations; periodontal pathogens; beta lactams; moxifloxacin
1. Introduction
Due to increased and often unrestricted consumption of antibiotics both in humans and in animal
husbandry, the development of resistance against antibiotics has become a global healthcare threat
leading to higher medical costs, prolonged hospital stays, and increased mortality [1,2]. There is an urgent
need for change in the prescription and use of antibiotics [3,4]; however, so far, strategies based on
antibiotic stewardships, infection prevention and control programs were unable to control the increase
in antimicrobial resistance [5]. As there is also a lack of new antimicrobials that are effective against
resistant bacteria, the knowledge of factors contributing to the spread of resistant microorganisms is of
high importance [6].
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A recent analysis in the U.S showed that dentists account for 13.2% of all antibiotic prescriptions
among the antibiotic prescriptions providers, with periodontists having a higher prescription rate
than general dentists [7]. Periodontal diseases are polymicrobial oral infections by predominantly
Gram-negative capnophilic and anaerobic subgingival bacterial species such as Aggregatibacter
actinomycetemcomitans andPorphyromonas gingivalis [8]. The virulence factors ofA. actinomycetemcomitans,
associated with severe periodontitis in young age, include leukotoxin, cytolethal distending toxin, and
lipopolysaccharide [9]. P. gingivalis has high proteolytic activity and is considered a keystone pathogen
in the initiation and progression of periodontal disease [10]. Besides the mechanical debridement of
infected periodontal pockets, clinical treatment protocols for severe forms of periodontitis often involve
the adjunctive use of antibiotics like amoxicillin, metronidazole, azithromycin, and tetracycline [11,12].
The objective of this study was to determine the antibiotic susceptibility among clinical isolates of
A. actinomycetemcomitans and P. gingivalis isolated from Swiss periodontitis patients over four decades.
2. Results
In total, 57 A. actinomycetemcomitans and 56 P. gingivalis strains could be included in this study.
Only one isolate per patient was considered in the analysis. As P. gingivalis strains were only available
from 1990 on, isolates were not equally distributed over the different decades (Table 1).
Table 1. Temporal distribution of A. actinomycetemcomitans and P. gingivalis isolates.
Years A. actinomycetemcomitans P. gingivalis
1980–1989 22 na
1990–1999 19 25
2000–2009 8 11
2010–2017 8 20
na: no isolates available.
Table 2 shows the MIC50 and MIC90 values for the tested antimicrobials. The results confirm
the high resistance of A. actinomycetemcomitans against clindamycin (≥8 µg/mL) and metronidazole
(≥32 µg/mL). The MIC90 values for ampicillin and amoxicillin/clavulanic acid were 2 µg/mL and
2/1 µg/mL, respectively, whereas the MIC50 and MIC90 values of the other antimicrobials were low.
P. gingivalis yielded low MIC50 (0.0625–0.5 µg/mL) and MIC90 (0.125–2 µg/mL) values for all the
antimicrobials tested.
Table 2. MIC50 and MIC90 values (µg/mL) for A. actinomycetemcomitans and P. gingivalis strains.
Antibiotic A.actinomycetemcomitans P. gingivalis
MIC50 MIC90 MIC50 MIC90
Ampicillin 0.5 2 0.125 0.5
Amoxicillin/Clavulanic Acid 0.5/0.25 2/1 0.5/0.25 0.5/0.25
Clindamycin 8 >8 0.0625 0.25
Azithromycin 0.25 1 0.250 0.5
Ertapenem 0.125 0.25 0.125 0.25
Doxycycline 0.5 1 0.25 1
Moxifloxacin 0.0625 0.125 0.0625 0.125
Metronidazole 32 >32 0.25 2
The susceptibility of A. actinomycetemcomitans (Figure 1) and P. gingivalis (Figure 2) to most of
the antimicrobials did not change over time. A. actinomycetemcomitans showed statistically significant
differences for azithromycin (p = 0.002) and clindamycin (p = 0.004). In particular, azithromycin
exhibited the highest cumulative MIC values in the first decade (1980–1989), while clindamycin
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yielded the lowest cumulative MIC values in the last decade (2010–2017). Regarding P. gingivalis,
statistically significant differences were observed for clindamycin (p = 0.006), ertapenem (p = 0.014),
and doxycycline (p = 0.040).
The cfxA gene was not detected in any of the tested P. gingivalis and A. actinomycetemcomitans
strains and the nitrocefin test was negative for all tested isolates. The tetQ gene was identified in two
P. gingivalis strains, one of which yielded a MIC of 1 µg/mL for doxycycline.
Two P. gingivalis strains isolated in the last decade (2010–2017) showed the highest MIC values.
One isolate was ermF-positive and had MIC values higher than 8 µg/mL, 2 µg/mL, and 0.25 µg/mL
for clindamycin, azithromycin, and moxifloxacin, respectively. The second isolate had a high MIC
value of 4 µg/mL for moxifloxacin. Sequence analysis of the quinolone resistance-determining region
(QRDR) of the gyrA gene confirmed a gene mutation, namely a Ser-83 ≥ Phe substitution [13].
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(1980–1988; blue), 1990 (1990–1999; green), 2000 (2000–2009; purple), and 2010 (2010–2017; orange).
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Figure 2. Cumulative minimal inhibitory concentrations against Porphyromonas gingivalis isolates.
Results are shown for the antibiotics ampicillin, amoxicilli /cl vulanic acid, clindamycin, azithromycin,
ertapenem, doxycycline, moxiflox cin, and metron dazole during the dec des 1990 (1990–1999; green),
2000 (2000–2009; purple), an 2010 (2010–2017; orange).
3. Discussion
Overall, an increase of MIC values among the tested A. actinomycetemcomitans and P. gingivalis
isolates over the 37-year period could not be observed. Although only a limited number of clinical
isolates was analyzed in this study, the results are in agreement with a previous Swiss study, where
no increase was detected in antibiotic-resistant oral bacteria after comparing Prevotella intermedia and
A. actinomycetemcomitans strains isolated during 1991–1994 with isolates collected during 2001–2004 [14].
The absence of an increasing antibiotic resistance among the tested bacteria associated with periodontal
disease over the last 37 years might be attributed to the restricted use of antibiotics in the treatment
of severe forms of chronic periodontitis at the dental university clinics of Basel, Bern, and Zurich.
A questionnaire among dentists in dental practices in Switzerland confirmed that the prescription of
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antibiotics in Switzerland is selective and cautious [15]. In contrast, many prescriptions in the United
States are considered to involve ‘inappropriate’ use of antibiotics [16].
In regard to the resistance profiles of A. actinomycetemcomitans and P. gingivalis, our results are
comparable to data from the Netherlands [17]. Similarly, a high sensitivity of P. gingivalis to antibiotics
commonly used in dentistry is found in the United States and Norway, whereas a significant amount of
A. actinomycetemcomitans strains is resistant to tetracycline [18,19]. Antibiotic resistances of other oral
anaerobic bacteria are of increasing clinical importance as well. In particular, oral Prevotella spp. isolated
from periodontal abscesses were resistant to metronidazole (9.5%), amoxicillin (30.9%), clindamycin
(38.1%), and doxycycline (4.8%). Their increased resistance was often related to the presence of nim, cfxA,
ermF, and tetQ genes [20]. In another study, oral isolates of P. intermedia and Prevotella buccae yielded
high MIC values for doxycycline and tetracycline [21]. In our study, the ermF gene was identified in
accordance with a phenotypical resistance to clindamycin only in one P. gingivalis isolate. The tetQ gene
was present in only one of the two respective P. gingivalis isolates associated with a slightly elevated MIC
value to doxycycline.
In subgingival plaque, bacteria are organized as a complex biofilm. In general, MIC values are
higher for bacteria in biofilms than for planktonic cultures [22]. Various biofilm models exist for analyzing
antimicrobial susceptibility and first attempts are being made to determine the antibiotic concentrations
that can inhibit all microorganisms present in a polymicrobial sample [23,24].
One of the P. gingivalis strains from our study, a strain isolated from a patient with rheumatoid
arthritis in the decade 2010–2017, showed an elevated MIC value for the fluoroquinolone, moxifloxacin,
which was due to a mutation in the gyrA gene. No resistance to quinolones has been reported in clinical
oral isolates of P. gingivalis so far. However, moxifloxacin resistance in P. gingivalis strains could be
induced in vitro by exposing P. gingivalis strains to subinhibitory concentrations of fluoroquinolones.
In this study, published in 2004, resistance was shown to be due to a Ser-83 ≥ Phe substitution in
the gyrA gene of the QRDR [13]. At that time, the adjunctive use of moxifloxacin was promoted in
periodontal therapy because of the antibiotic’s ability to penetrate into tissues and cells of anaerobic
periodontal pathogens in both the planktonic as well as biofilm state [22,25].
Meanwhile, due to the increasing development of resistance to quinolones which is associated
with the overuse of this antibiotic class, personalized and restricted prescription is considered to be
crucial [26]. Interestingly, the P. gingivalis isolate with the gyrA mutation was isolated from a patient
with rheumatoid arthritis. Since quinolones are rarely used in periodontal therapy in Switzerland,
this resistance may be associated with the treatment of non-oral bacteria. Certainly, the detection of
quinolone-resistant clinical isolates of P. gingivalis should raise concerns about the use of antibiotics in
the treatment of bacterial-induced oral infections such as periodontitis. Inappropriate use of antibiotics
may not only lead to an increase in adverse events and healthcare costs, but might also contribute to
the selection of antibiotic-resistant bacteria.
4. Materials and Methods
4.1. Isolation of Bacteria
All clinical isolates were obtained from subgingival biofilm samples of Swiss periodontitis patients
between 1980 and 2017 and stored at −80 ◦C in the respective strain collections of the oral microbiology
diagnostic laboratories in Basel, Bern, and Zurich. The most recent clinical strains originate from two
studies approved by the Ethics Committee Bern (#236/2010 and #096/2015). The identification of species
changed over time; therefore, the species identity of all the strains was confirmed by using specific
16S rDNA-real-time PCR analysis [27]. In total, 57 A. actinomycetemcomitans and 56 P. gingivalis strains
could be included in the analysis. For resistance testing, these isolates were then cultured on Tryptic
Soy agar plates with 5% sheep blood (Oxoid, Thermo Fisher Diagnostics AG, Pratteln, Switzerland),
and incubated anaerobically.
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4.2. Determination of the Minimal Inhibitory Concentration (MIC) and Resistance Testing
MICRONAUT-S Anaerobe MIC plates (Merlin Diagnostica, Bornheim-Hersel, Germany) were used
for determining the minimal inhibitory concentrations (MICs) for the following antibiotics:ampicillin
(range: 0.063–8 µg/mL), amoxicillin/clavulanic acid (range: 0.5/0.25–64/32 µg/mL), clindamycin (range:
0.063–8µg/mL), ertapenem (range: 0.125–16µg/mL), doxycycline (range: 0.125–16µg/mL), metronidazole
(range: 0.25–32 µg/mL), and moxifloxacin (range: 0.063–8 µg/mL). The tests were performed according to
the manufacturer’s recommendations. For azithromycin (range: 0.063–8 µg/mL), a microbroth dilution
assay was used.
Elevated MICs were confirmed by an agar dilution technique using Wilkins Chalgren agar plates
with 5% laked horse blood (Oxoid, Thermo Fisher Diagnostics AG, Pratteln, Switzerland). All the strains
were screened for beta-lactamases using nitrocefin discs as described by the manufacturer (Sigma-Aldrich,
Buchs, Switzerland). The presence of the cfxA, ermF, and tetQ genes was determined by real-time PCR
assays using GoTaq® qPCR Master Mix (Promega AG, Dübendorf, Switzerland) and specific primers [28].
A strain with an elevated resistance against moxifloxacin was forwarded to PCR analysis of the gyrA
quinolone resistant determining region (QRDR) [13] and subsequent sequencing of the PCR product
(Microsynth AG, Balgach, Switzerland).
The MIC results were interpreted using EUCAST breakpoints for anaerobic bacteria in the case of
P. gingivalis. In the case of A. actinomycetemcomitans, the interpretive criteria for the HACEK-group
were applied [29]. The distribution of the MIC values is shown by presenting the cumulative MIC
values and by calculating the necessary concentrations to inhibit 50% (MIC50) and 90% (MIC90) of the
respective strains.
4.3. Statistical Analysis
The descriptive analysis and Chi2 test were done using SPSS 24.0 (IBM, Chicago, IL, USA).
5. Conclusions
There was no significant increase in the antibiotic resistance among the oral bacterial isolates
tested. However, the detection of resistant P. gingivalis isolates underlines the need to optimize the
antibiotic therapeutic protocols in dentistry.
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